PDF icon Download PDF
J Pediatr Infect Dis 2017; 12(03): 145-146
DOI: 10.1055/s-0037-1602827
Foreword
Georg Thieme Verlag KG Stuttgart · New York

Role of Immune Changes in Neonatal Infections

Said A. Omar
1   Division of Neonatology, Department of Pediatrics and Human Development, Michigan State University, College of Human Medicine, East Lansing, Michigan, United States
› Author Affiliations
Further Information

Publication History

08 December 2016

26 December 2016

Publication Date:
02 June 2017 (online)

Also available ateRef
   Permissions and Reprints
Preview

Neonatal infection remains one of the main problems affecting sick neonates admitted to the neonatal intensive care units and is associated with high mortality and morbidities. Sick neonates with an infection have associated changes in innate and adaptive immune response that markedly affect their outcome. The increase of proinflammatory and decrease in anti-inflammatory mediators are believed to play a significant role in the outcome of multiple neonatal conditions such as bronchopulmonary dysplasia, necrotizing enterocolitis, white matter injury, and cerebral palsy and long-term developmental delay.

T-cell immune system is immature at birth with a marked predominance of naive T-cells. However, neonates are capable of increasing the expression of memory T-cells in response to infection. The increase in memory T-cells expression persisted after recovery from sepsis.[1] Memory T-cells are responsible for the rapid and enhanced immune response on reexposure to previously encountered antigens including autoimmune and allergic diseases, or infectious agents such as bacteria and viruses.[2] [3]

Understanding the immunologic changes during neonatal infection and the role of proinflammatory cytokines in the survival of these critically sick neonates at the expense of extensive tissue damage may play a significant role in our future ability to improve the outcome of these sick neonates.

The postnatal development of the immune system in neonates involves a transition from higher levels of immune regulatory cytokines to higher levels of inflammatory cytokines. Newborns who have defects in upregulating proinflammatory cytokines are more susceptible to infection. An imbalance of proinflammatory and anti-inflammatory cytokines is associated with an increased risk of infection. Characterization of these cytokines can help in developing therapeutic modules to make these newborns more resilient against microbial invaders.[4]

In this special issue of the journal, the role of immunological changes during neonatal infection is reviewed. In the first article, the biology of T-helper cells and their role in neonatal infection is reviewed. These T-helper cells are central players of adaptive immune system that provides protection and surveillance against infections. The differentiation of naive T cells into various subsets of T-helper cells such as Th1, Th2, Th17, and Treg depends on orchestrated and coordinated interplay of cytokines; cytokine-mediated signaling, core, and inducible transcription factors.[5]

In the second article, chorioamnionitis-induced immunological changes and their effects in neonatal outcome are reviewed. This term implies that a pregnant woman has an “inflammatory or an infectious” disorder of the chorion, amnion, or both.[6] [7] Chorioamnionitis is the inflammation of the placenta with associated high levels of cord blood proinflammatory cytokines.[8] [9] The role of the high levels of the chorioamnionitis-associated proinflammatory cytokines in neonatal morbidities such as white matter injury or necrotizing enterocolitis was reviewed.[10] [11] In the third article, the immunological changes during group B streptococcal (GBS) infection in neonates are reviewed. GBS causes invasive infection in neonates and is a leading cause of pneumonia, neonatal sepsis, meningitis, and a high rate of death.[12] The article emphasizes that a greater understanding of the interaction between GBS and the neonatal immune system may aid in the development of novel therapies or preventative measures for invasive GBS disease.

In an attempt to treat these sick extremely premature neonates with immunologic agents, such as granulocyte colony-stimulating factor (G-CSF) or intravenous immunoglobulin (IVIG) data were presented in the fourth and fifth articles. The fourth article is a prospective study to examine the role of recombinant rhG-CSF in modulating the inflammatory response in extremely low gestational age neonates. G-CSF serves an important cellular role in production and maturation of neutrophils as well as a clinical role in response to infection and inflammation and primes granulocytes to enhanced immune defenses.[13] [14] [15] [16] The study showed that rhG-CSF use is associated with lower tumor necrosis factor (TNF) levels. The study concluded that during critical illness or sepsis, rhG-CSF might have benefits as a drug that can elevate neonatal neutrophil number and function while simultaneously limiting collateral injury due to TNF.

In the fifth article, white blood cells, absolute neutrophil count, and monocytes increased in a response to rhG-CSF and IVIG combination treatment in extremely low-birth-weight neonates with necrotizing enterocolitis without effect on survival, need for surgery, time to reach full feed, or time to discharge home.

The advance in the field of genomics, transcriptomics, and proteomics will enhance our ability to understand the specific immunologic changes during neonatal infections. This understanding will help us better treat neonatal infections and develop better antibiotics stewardship, as reviewed in the sixth article, to avoid the side effects associated with the overuse of these antibiotics.